Search Results
Sep 09, 2026, 02:00 ET Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs,
More news about: Evotec SE
Sep 07, 2026, 11:06 ET Stem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen Research
Stem Cells MarketIn March 2026, Applied StemCell and Cellipont Bioservices announced a collaboration aimed at speeding up development of iPSC-derived cell therapies, pairing engineering and banking capabilities with manufacturing and regulatory support.In January 2026, Aspect Biosystems
More news about: Wissen Research LLC
Sep 07, 2026, 08:00 ET Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio
latest review cases for a range of products incorporating advanced bio technologies, including the world's first approved induced pluripotent stem cell (iPSC) therapy, coordinating the direction of global review and regulation in the field of advanced biopharmaceuticals.In addition, at a bilateral
More news about: The Korea Herald
Sep 02, 2026, 02:04 ET Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs,
More news about: Evotec SE
Aug 18, 2026, 09:00 ET Kenai Therapeutics Appoints Mark Gergen to Board of Directors
pioneering next generation approaches to cure neurological conditions. By leveraging a proprietary, Nobel Prize-winning induced pluripotent stem cell (iPSC) platform, Kenai is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Kenai's
More news about: Kenai Therapeutics/BIOCOM
Aug 17, 2026, 08:00 ET 28bio Launches CNS-3D Plasticity Organoids to Assess Drug Effects on Human Learning and Memory
Plasticity Organoids pair two human iPSC-derived cortical organoids in a custom electrode array plate, forming a connected neural network that can be trained via closed-loop electrical stimulation.
More news about: 28bio
Aug 06, 2026, 11:33 ET CureC9 and BrainXell Partner to Advance ALS and FTD Research Through Patient-Driven Innovation
lateral sclerosis (ALS) and frontotemporal dementia (FTD), has partnered with BrainXell, Inc. to expand access to high-quality, patient-derived human iPSC models for the global research community.
More news about: BrainXell, Inc
Aug 06, 2026, 02:16 ET Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs,
More news about: Evotec SE
Aug 05, 2026, 08:00 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
provides CDMO services for a broad spectrum of CGT products, including plasmids, lentivirus, cell therapies (CAR-T, TCR-T, UCAR-T, NK, CAR-NK, MSC, TIL, iPSC, etc.), in vivo CAR-T, mRNA, and exosomes. This supports clients across the entire CGT product lifecycle, from IND filing and clinical research
More news about: Porton Advanced
Aug 05, 2026, 03:00 ET NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
for a wide range of cell therapies. NueCell Bio works across a broad spectrum of groundbreaking science in this field, including CAR-T, stem cells, iPSC-derived therapies, gene-edited cells, and tissue repair platforms – supporting both autologous and allogeneic products.NueCell Bio is headquartered
More news about: NueCell Bio
Aug 05, 2026, 03:00 ET NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
for a wide range of cell therapies. NueCell Bio works across a broad spectrum of groundbreaking science in this field, including CAR-T, stem cells, iPSC-derived therapies, gene-edited cells, and tissue repair platforms – supporting both autologous and allogeneic products.NueCell Bio is headquartered
More news about: NueCell Bio
Aug 04, 2026, 08:21 ET FDA Grants Fast Track Designation to Xellsmart Off-The-Shelf Cell Therapy for Parkinson's Disease
leading position in developing iPSC-derived cell therapies for neurological conditions including Parkinson's disease and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). With steady advancement of Sino-US registrational programs, this homegrown Chinese iPSC-derived cell therapy, with
More news about: XellSmart Biopharmaceutical Co., Ltd.
Jul 30, 2026, 08:30 ET Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson's Disease
transformative. Aspen previously received FDA Fast Track designation for sasineprocel. These designations underscore its clinical promise, innovative iPSC-derived cell therapy platform, and the potential to modify the course of PD.The RMAT designation for sasineprocel is based on results from the
More news about: Aspen Neuroscience, Inc.
Jul 21, 2026, 15:20 ET Team SIG's Daniel Horner Notches 15th National Championship
achievements, including his 8 Sniper Championships, 2 All Army Championships, 2 IDPA National Championships, IPSC Shotgun National Championship, NRA World Shooting Championship, and Team USA gold at the IPSC World Shoot. About SIG SAUER Inc.SIG SAUER Inc. is a leading manufacturer
More news about: SIG SAUER, Inc.
Jul 20, 2026, 10:31 ET Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight
mesenchymal precursor cells (MPCs) from Mesoblast, autologous disc-derived cells such as BRTX-100, induced pluripotent stem cell (iPSC)-derived nucleus pulposus-like cells from DiscGenics, and native tissue allografts from VIVEX. Together, these approaches represent varying
More news about: DelveInsight Business Research, LLP
Jul 13, 2026, 08:15 ET Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 Carriers
HT-4253 inhibited LRRK2 autophosphorylation and Rab10 phosphorylation, confirming target engagement. In iPSC-derived microglia (2D and 3D organoids), it reduced pro-inflammatory cytokine secretion; in iPSC-derived neurons, it decreased tau phosphorylation; and it restored phagocytic function in interferon-γ–exhausted
More news about: Halia Therapeutics
Jul 09, 2026, 13:09 ET Stem Cell Banking Market Surges to USD 28.9 Billion by 2033, Propelled by 12.4% CAGR - Verified Market Reports®
repositories.On the innovation frontier, induced pluripotent stem cell (iPSC) technology represents perhaps the most disruptive force within the market's competitive value chain. By reprogramming adult somatic cells into a pluripotent state, iPSC platforms eliminate many ethical barriers historically associated
More news about: Verified Market Reports
Jul 08, 2026, 09:38 ET Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
The platform is characterized by:Flexible Cell Culture Systems: supports multiple cell lines including HEK293, MSC, K562, and iPSC, enabling sponsors to select the optimal cell source for their therapeutic application.Scalable and Robust Processes: scalable from 2L to 50L
More news about: Porton Advanced
Jul 08, 2026, 09:00 ET Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
The platform is characterized by:Flexible Cell Culture Systems: supports multiple cell lines including HEK293, MSC, K562, and iPSC, enabling sponsors to select the optimal cell source for their therapeutic application.Scalable and Robust Processes: scalable from 2L to 50L
More news about: Porton Advanced
Jul 08, 2026, 07:00 ET RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions
in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions. The
More news about: RoosterBio, Inc.
Jul 07, 2026, 08:00 ET Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson's Disease
pioneering next generation approaches to cure neurological conditions. By leveraging a proprietary, Nobel Prize-winning induced pluripotent stem cell (iPSC) platform, Kenai is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Kenai's
More news about: Kenai Therapeutics/BIOCOM
Jun 30, 2026, 09:03 ET Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson's Disease
clinical trial designed to evaluate the safety, tolerability, and potential efficacy of sasineprocel, an autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuron precursor cell (DANPC) therapy. Sasineprocel is designed to replace and restore damaged neural circuitry in patients with Parkinson's disease
More news about: Aspen Neuroscience, Inc.
Jun 30, 2026, 02:16 ET Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs,
More news about: Evotec SE
Jun 24, 2026, 02:04 ET UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy
solidifies UniXell's unique dual-pathway clinical strategy covering personalized autologous and scalable off-the-shelf allogeneic iPSC therapeutics. UX-DA003 is an allogeneic iPSC-derived midbrain dopaminergic progenitor cell therapy, built upon UniXell's independently developed core technologies - the
More news about: Unixell Biotech
Jun 23, 2026, 08:04 ET Sparkling Sciences Obtains International INCI Certification for iPSC Exosome
international INCI certification for iPSC Exosome and completed Kyoto University's patent licensing agreement. INCI Name: Human Mesenchymal Stem Cell-Derived Induced Pluripotent Stem Cell Exosomes (INCI ID: 41693)This certification recognizes Sparkling Sciences' iPSC Exosome for applications in
More news about: Sparkling Sciences Co., Ltd.